Trial · NCT06071052
TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens
NCT06071052, Phase 2, Completed, First Affiliated Hospital, Sun Yat-Sen University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens. Trials, record NCT06071052. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06071052
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens
- NCT number
- NCT06071052
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 21 participants, actual
- Lead sponsor
- First Affiliated Hospital, Sun Yat-Sen University
- Conditions
- Liver Metastasis Colon Cancer
- Interventions
- TACE and HAIC Combined With Regorafenib
- First posted
- 2023-10-06
- Last updated
- 2026-03-05
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective response rate, ORR | through study completion, an average of 1 year | The objective response rate is defined as the proportion of patients in complete and partial remission, and the treatment response is based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST) |
| Primary | Time to progression, TTP | through study completion, an average of 1 year | It is defined as the time from randomization to disease progression throughout the entire experiment. Patients who withdraw or are lost will be treated as deleted, and their known last survival date will be used as the final survival time. Patients who did not make progress at the end of the study will be treated as deleted, with the known last date of survival as the final survival time. Death will also be treated as deletion, with the time of death as the final survival time. |
| Secondary | Overall Survival, OS | through study completion, an average of 1 year | It is defined as the time from randomization to death from any cause throughout the entire experiment. Patients who withdraw or are lost will be treated as deleted, and their known last survival date will be used as the final survival time. Patients who were still alive at the end of the study will also be treated as deleted, with the known last date of survival as the final survival time. |
| Secondary | Negative conversion rate of the tumor index | through study completion, an average of 1 year | It is defined as the ratio of the number of cases with tumor indicators CEA and CA-199 returning to normal range (CEA ≤ 5.0 ug/L, CA199 ≤ 35.0 U/mL) after treatment to total number of cases × 100%. Higher scores mean a better outcome. |
| Secondary | Transformation and resection rate and ablation rate of liver metastases | through study completion, an average of 1 year | It is defined as the ratio of the number of cases with liver metastases that have transformed from non resectable (ablation) to resectable (ablation) after treatment to total number of cases × 100%. Higher scores mean a better outcome. |
| Secondary | Safety evaluation | through study completion, an average of 1 year | It is defined as the occurrence of one of the ≥ 3 levels of hematological or non hematological toxic events (including but not limited to liver function damage, hematological system damage, hypertension, diarrhea, proteinuria, hand foot syndrome, etc.). The severity of adverse events will be graded according to the Common Adverse Reaction Terminology Standard (CTCAE v4.03) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06071052
GET https://conductscience.org/api/trials/v1/NCT06071052/registered